I-Mab (IMAB) Stock Analysis

I-Mab (IMAB) is a publicly traded company in the HEALTHCARE sector. It trades at $4.63. This page summarizes the public market data, fundamentals, and frequently asked questions for IMAB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

I-Mab currently has a Bullish sentiment score of 0.22.

About I-Mab

I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the pot...

GNG Research Analysis

GNG Research scores I-Mab (IMAB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMAB.

Frequently Asked Questions

Does IMAB pay dividends?

I-Mab (IMAB) does not currently pay a regular dividend.